37% of patients with high-risk oral leukoplakia treated with preventative immunotherapy had proliferative leukoplakia regression and demonstrated favorable overall cancer-free survival. Glenn Hanna, MD, explains more.
Dr. Hanna completed his fellowship training in hematology and medical oncology at Dana-Farber Cancer Institute in 2016. Prior to this, he earned his medical degree from Georgetown University School of Medicine in 2010, where he graduated ...
